New study aims to protect vulnerable infants from dangerous RSV
NCT ID NCT06851806
First seen Nov 17, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This study is testing the safety of a monthly injection called palivizumab in infants and children under 2 years old who are at high risk for severe RSV disease. Participants will receive up to 5 injections over the study period. The goal is to see how safe the drug is and to track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGHyderabad, 500084, India
-
Research Site
NOT_YET_RECRUITINGPune, 411006, India
Conditions
Explore the condition pages connected to this study.